Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Fidelio Capital in connection with its investment in Hemfrid
Mandate

Vinge has advised Fidelio Capital in connection with its investment in Hemfrid

August 27, 2021 M&A IT, Telecommunications and Outsourcing Corporate Commercial Employment and Benefits Real Estate and Construction Intellectual Property

Vinge has advised Fidelio Capital AB in its majority investment in Hemfrid i Sverige AB, the leading player within the home service industry in Sweden, with a revenue exceeding MSEK 700 and more than 2,000 employees in 2020. The transaction is subject to customary regulatory approvals and is expected to be completed during the second half of 2021.

Vinge’s team consisted of, among others, Daniel Rosvall, Jonas Bergström, Joacim Rydergård, Filip Öhrner, Christa Anttila, Hannah Kajlinger, Annie Fällström and Amanda Steen (M&A), Karolina Fuhrman and Mika Jordan (Corporate Commercial and IT), Felizia Wiker (IPR), Gustav Lindgren and Carl Östlund (Employment), Karolina Cohrs (Real Estate), and Sara Dahlros Sköld (VDR Assistant).

Related

Vinge advises Vinci Concessions SAS and its subsidiary SunMind SAS in connection with its acquisition of Helios Nordic Energy AB from Magnora ASA, management and early investors

 Helios Nordic Energy specialises in developing solar farms and batteries to store energy until they become Ready to Build in the Nordics and Baltics.
May 30, 2024

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (“SBB”) in connection with SBB establishing a new joint venture with Castlelake, LP (“Castlelake”).
May 28, 2024

Vinge advises Calliditas Therapeutics in connection with Asahi Kasei Corporation’s public takeover offer

 On 28 May 2024, Asahi Kasei Corporation announced a public takeover offer to the shareholders and holders of American Depositary Shares in Calliditas Therapeutics AB (publ) (”Calliditas Therapeutics”) to acquire all shares and American Depositary Shares (each representing two shares) in Calliditas Therapeutics.
May 28, 2024